MedTrace Logo

Methylene Blue in Severe Sepsis and Septic Shock

NCT01797978 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 354

Last updated 2015-11-18

No results posted yet for this study

Summary

This study is to see whether the intravenous administration of methylene blue improves the outcome in severe sepsis and septic shock.

Conditions

  • Severe Sepsis
  • Septic Shock

Interventions

DRUG

Intravenous methylene blue administration

Initial history taking and physical examination --\> enrollment --\> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs

DRUG

Placebo

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Kyuseok Kim, MD · Professor, department of emergency medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2016-01-31
Completion
2017-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01797978 on ClinicalTrials.gov